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In vivoA pioneer series of copper(II) complexes bearing planar phenanthroline-modified aromatic ligands and
steroid (ethynylestradiol and ethisterone) with generic formula [Cu(N \ N)(steroid)](NO3)2 where
N \ N is DPQ, DPPZ and DPPN and steroid is estradiol or testosterone, were synthetized, characterised
and screened in vitro and in vivo as antimicrobial agents against Staphylococcus aureus and methicillin
resistant Staphylococcus aureus (MRSA). Toxicity studies revealed notable antibacterial activity of the
copper – based compounds, which is significantly increased in vivo by the presence of the steroid moiety.
Toxicity profiling was estimated in vitro versus Gram-positive (Staphylococcus aureus) and MRSA and
in vivo in Galleria mellonella larvae infected with S. aureus. Results showed the complexes to be active
against S. aureus and MRSA in vitro (MIC50 average value of 2.46 and 97 lM in S. aureus and MRSA,
respectively) and to be active when larvae infected with S. aureus were administered the agents.
 2018 Elsevier B.V. All rights reserved.1. Introduction
The bacterium Staphylococcus aureus is a Gram positive body
commensal which has the ability to survive in a wide variety of
environments [1], and this contributes to its ability to induce a
range of superficial and systemic infections. S. aureus possesses a
number of virulence factors that contribute to its ability to colonise
tissue including the presence of a capsule, the expression of adhe-
sins, the secretion of a range of toxins and immunomodulators
which disrupt the host’s immune response [2]. This bacterium is
present on approximately 30% of healthy individuals in the ante-
rior nares and on the skin, but a skin breach resulting from surgery
or trauma can result in a variety of skin infections, such as impet-
igo, or more serious diseases such as toxic shock syndrome and
sepsis [3,4]. S. aureus infection can be extremely difficult to treat
and up to 4% of cases can be fatal [3]. Treatment of S. aureus infec-
tions is hindered by the emergence of methicillin-resistant S. aur-
eus (MRSA) and due to the increasing incidence of resistance to
conventional antimicrobials there is a renewed interest in the
development of novel metal based drugs as antimicrobial agent [5].
Despite the classic organic based antibacterial agents, metal
complexes are an excellent alternative and in particular Cu(phen)
derivatives. In the last twenty years the antimicrobial activity ofCu(phen) complexes have been deeply investigated; double
charged copper with planar chelating ligands exhibit growth inhi-
bitory activity against Staphylococcus aureus (MIC  4.0–7.9 lM)
and to a lesser extent against Escherichia coli [6–13]. It is still not
completely clear what role the planar ligands play in the antimi-
crobial activity of the corresponding metal based drugs. Indeed,
metal complexes with substituted planar aromatic ligands (i.e.
DPQ, DPPZ and DPPN, Scheme 1) show an increased interaction
via intercalation with the DNA and Cu(II) derivatives and also show
artificial nuclease activity but this could not be related with the
antimicrobial properties [14–16]. Mitochondrial membrane dam-
age and p53 upregulation are also alternative possible pathways
of action. Creaven et al. showed that Cu(phen) complexes function-
alised with acetic acids are able to inhibit respiration, reduce level
of ergosterol and alter the cytochrome c content [12]. Considering
these aspects, here we report the syntheses, characterization and
antimicrobial evaluation of a series of Cu(II) complexes with
chelating planar ligands further functionalised with steroids
(testosterone and estradiol). We recently showed that the modifi-
cation of Au(I)–NHC (N-Heterocyclic Carbenes) with steroids
derivatives is a promising strategy to enhance the antibacterial
activity of the related complexes [17]. In the work presented here
the Cu(II) cationic complexes were evaluated as antibacterial
agents in vitro against S. aureus and MRSA and in vivo using Galleria
mellonella larvae.
Scheme 1. Structures of [Cu(ES-5-phen)(DPQ)]2+ 4, [Cu(EE-5-phen)(DPQ)]2+ 5, [Cu
(ES-5-phen)(DPPZ)]2+ 6, [Cu(EE-5-phen)(DPPZ)]2+ 7, [Cu(ES-5-phen)(DPPN)]2+ 8,
[Cu(EE-5-phen))(DPPN)]2+ 9.
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tional similarities to the innate immune response of mammals
[18–20] and consequently insects can be used to assess the viru-
lence of microbial pathogens or the in vivo efficacy of antimicrobial
drugs and give results similar to those obtained using mammals
[21,22]. Larvae of Galleria mellonella are a popular choice for these
types of tests and are inexpensive to purchase, and give rapid
results [18]. G. mellonella larvae have previously been used to
demonstrate the in vivo activity of novel metal based drugs against
pathogenic bacteria and fungi [23,24] and show a strong correla-
tion with results obtained in rats [25].
The aim of this work was to analyse the in vitro effects of the six
metal complexes on Staphylococcus aureus and MRSA, to evaluate
the toxicity of the compounds in Galleria mellonella larvae and to
examine if the compounds showed any therapeutic properties
when larvae had been pre-inoculated with microbial infections.2. Material and methods
All reagents and reactants used were purchased from commer-
cial sources. The two sources used were Sigma Aldrich and Tokyo
Chemical Industry. DPQ (Dipyrido[3,2-f:20,30-h]quinoxaline), DPPZ
(Dipyrido[3,2-a:20,30-c]phenazine), DPPN (Benzo[I]dipyrido[3,2-
a:20,30-c]phenazine) and tetrakis triphenylphosphine Palladium(0)
were synthetized as previously reported [26–29].
All solvents were used without further purification. The DMF
was dried using 4 Ã. . . molecular sieves, it was then decanted into
a round bottom flask and kept under high vacuum using a Schlenk
line while immersed in liquid nitrogen. The DMF was then flushed
with nitrogen gas. This step was repeated a minimum of three
times for the Sonogashira coupling reaction to obtain ES-5-phen
and EE-5-phen.
All NMR spectra were recorded on a Bruker Advance spectrom-
eter with the probe at 293 K, operating at 500 MHz for the 1H
nucleus. Proton signals were assigned with the help of 2D NMR
experiments (COSY). Spectra were recorded in CDCl3 using Me4Si
as the internal standard. All chemical shifts are reported in ppm.
Infrared (IR) spectra were recorded in the region 4000 – 400
cm1 on a Perkin Elmer precisely spectrum 100 FT/IR spectrometer.
The solid samples were run using ATR.
Elemental analyses (carbon, hydrogen and nitrogen) were per-
formed with a PerkinElmer 2400 series II analyzer. ESI mass spec-tra were recorded in positive mode with a Waters LCT Premier XE
Spectrometer.2.1. Assessment of antibacterial activity of novel complexes
The complexes were dissolved in 1 mL DMSO to give a stock
concentration of 5 mg/mL. Nutrient broth (100lL) was added to
each well of a 96 well plate. Each drug was serially diluted on
the plate giving a concentration range 150 – 0.59 lM. Bacteria
were grown overnight and the OD600 was adjusted to 0.1 (equiva-
lent to cell density of 4  107/ml). Bacterial cells (100 lL) were
added to each well and the growth was measured at 600 nm after
24 h at 37 C using a spectrophotometer (BioPhotometer). The
MIC50 values were calculated as the minimum concentration of
drug that inhibited growth by 50%.2.2. Inoculation of Galleria mellonella larvae
Sixth instar larvae of G. mellonella (Lepidoptera: Pyralidae, the
Greater Wax Moth) (Mealworm Company, Sheffield, England) were
stored in the dark at 15 C. 5 Larvae of the same age and weighing
0.3 g were inoculated with 20 lL of PBS containing cells 4  107
bacterial cell through the last pro-leg using a Myjector U100 insu-
lin syringe (Terumo Europe, Leuven, Belgium).2.3. In vivo toxicity assay
Larvae were injected with 20 lL of compound solution (150 –
0.59 lM) or 5% (v/v) DMSO through the last left pro-leg as
described. Larvae were incubated at 37 C for 24 h prior to quanti-
fying survival after 24, 48 and 72 h.2.4. Effect of compounds on survival of G. Mellonella larvae infected
with S. aureus
Larvae were injected with S. aureus through the last left proleg
as described. One hour post infection 20 ul of each compound solu-
tion (0.1 or 0.25 mg/ml) was administered. The control consisted of
larvae inoculated with the S. aureus. Larvae were incubated at 37 C
and survival was assessed at 24 and 48 h.3. Experimental
The starting [Cu(N \ N)(OH2)2](NO3)2 (1–3) complexes (where
N \ N is DPQ (1), DPPZ (2) or DPPN(3), See Experimental Part in
Supporting Information) where obtained by modifying a literature
procedure [21–23]. Briefly, Cu(NO3)23H2O and the corresponding
N \ N ligand where mixed in a 1.1 to 1 ratio in methanol and
refluxed for two hours. The slight excess of the Copper salt prevent
the formation of the more stable bis-adduct [Cu(N \ N)2](NO3)2.
The solid was obtained by addition of Et2O, isolated by filtration
and dried in vacuum (Supporting Information).
The phen-steroid derivatives of general formula ES or EE-5-
phen (where ES-5-phen and EE-5-phen are the Estradiol and
Testosterone derivatives, respectively) have been obtained by
Sonogashira coupling reaction between 5-Bromophenanthroline
and the correspondent commercial available alkyne derivative of
the steroids (See Scheme 2 and Supporting Information).
The final complexes [Cu(N \ N)(EE or ES-5-phen)](NO3)2 (4–9)
are depicted in Scheme 1 and were obtained by mixing the corre-
sponding [Cu(N \ N)(OH2)2](NO3)2 (1–3) and the corresponding
steroid-phen in a 1 to 1 ratio in DMF at 50 C overnight. The solids
were isolated by filtration after addition of Et2O and dried in vac-
uum (See Supporting Information).
Scheme 2. Synthetic pathway to produce ES-5-Phen using Sonogashira Coupling
Reaction.
Table 1
Antimicrobial activity of selected compounds. MIC50 [lM].
Compound S. aureus MRSA
4 4.7 ± 0.9 219 ± 10.4
5 1.5 ± 0.2 125 ± 9.5
6 2.1 ± 0.1 102 ± 8.9
7 2.0 ± 0.2 32 ± 3.2
8 2.5 ± 0.4 17.5 ± 1.5
9 2.0 ± 0.3 88 ± 7.8
S. Barrett et al. / Inorganica Chimica Acta 479 (2018) 261–265 2634. Results and discussion
Recent results from our group showed that the presence of ster-
oids (Estradiol and Testosterone) enhanced the in vivo antibacterial
activity of Au(I)–NHC carbene complexes [17]. Since Copper and in
particular Cu(II)-phenanthroline complexes are important antibac-
terial agents, we sought to combine these with steroid derivatives
to confirm the efficacy of this approach. Furthermore, the com-
plexes were functionalised with aromatic planar phenanthroline
derivatives ligands such as DPQ, DPPZ and DPPN.
The coordination sphere of the series of Cu(II) complexes anal-
ysed in this work is composed by two modified phenanthroline
scaffolds as depicted in Scheme 1. The alkyne steroids derivatives
(ES Ethinyl Estradiol and EE Ethiosterone) have been covalently
bound to phenathroline using the Sonogashira coupling reaction
with 5-Bromophenanthroline as shown in Scheme 2 for the Estra-
diol steroid (ES-5-phen).
The success of Sonogashira coupling reactions are highly depen-
dent upon the nature of the base and by the catalyst used as well as
by the inert and degassed use of solvent. After several attempts we
found that the best conditions were the use of the inorganic base
K2CO3, the use of a freshly prepared tetrakis-[Pd(PPh3)4] catalyst,
dry and degassed DMF at 100 C overnight under nitrogen atmo-
sphere (See Supporting Information). The success of the reaction
can be easily visualised in the 1H NMR spectrum by the disappear-
ance of the alkyne proton of the starting EE and ES at 2.55 ppm and
by the shift of the 1H in position six of the phenathroline that
moves upfield of 0.5 ppm in the ES/EE-5-Phen with respect the
starting 5-Bromophenanthroline (Fig. 1S and 2S).
The final complexes have been characterised by IR, Elemental
Analyses and Mass Spectrometry (Supporting Information). All
the mass spectra show a clearly visible peak with the isotopical
pattern of Cu in the positive region corresponding to the species
[MNO3]+ or [M2(NO3)+Cl]+ (Figs. 3-8S). The activity of the com-

















Fig. 1. Viability of Galleria mellonella larvae upon treatment with different
concentration of complex 4.the results indicate that all drugs were active against S. aureuswith
MIC50 values < 5 lM (Table 1) that are in line and even smaller
with most of the Cu(II) complexes reported in literature. [6–12]
The free estradiol and testosterone were non-active as previously
reported by us. [17] Among the series, the testosterone derivatives
(5, 7 and 9) are more potent (average MIC50 of 1.83 lM) with
respect the estradiol derivatives 4, 6 and 8 (average MIC50 of 3.1
lM). The planar ligand seems to play an important role because
the DPPZ derivatives 6 and 7 are the most active while DPQ (4
and 5) are the less potent with DPPN complexes (8 and 9) laying
between (average MIC50 of 2.05, 2.25 and 3.1 lM for DPPZ, DPPN
and DPQ, respectively). Two important factors are important:
lipophilicity and solubility. It is expected that the most lipophilic
complexes would be more potent due to higher intracellular
uptake; although DPPN derivatives 8 and 9 are more potent than
the DPQ analogues (4 and 5) they are less active than the DPPZ
(6 and 7) because solubility issues arise. Large and steric encum-
bered DPPN complexes are less soluble than the smaller DPQ and
DPPZ and this is the reason why intermediate DPPZ complexes
are the most potent. In the case of MRSA the complexes are much
less active (average MIC50 values of 97.4 lM) with some exception
such as compound 8 that has a MIC50 in the low micromolar region
(Table 1). The complexes were found to be inactive against the
Gram negative bacterium Pseudomonas aeruginosa and the yeast
Candida albicans (results not presented).
These promising results prompted us to investigate the in vivo
antimicrobial properties of these Cu-steroids complexes. MRSA
was not studied in vivo due to the poor results in vitro. G. mellonella
larvae are a useful tool in this kind of study because, as discussed in
the introduction, their immune system is similar to that of mam-
mals, they provide rapid and reliable results and there are no eth-
ical restrictions to their use. [19] The larvae are inoculated by
injecting the drug into the last left pro-leg and larval viability
can be easily determined by visualisation. Melanisation and lack
of movement indicates the inoculation proved fatal. (See Figs. 9
and 10S in Supporting information).
The first study analysed the toxicity of the Cu(II) series in
G. mellonella larvae. Previous work has established a strong corre-
lation between the toxicity of compounds in insect larvae and rats
[30] and compounds such as potassium nitrate [31] and caffeine
[32] are metabolised in a comparable manner in G. mellonella
larvae and mammals. The larvae were injected with increasing
concentrations of each compound and the viability was analysed
after 24, 48 and 72 h. Administration of doses of 0.1 mg/ml of each
drug to larvae had little or no effect on viability over 72 h. In the
case of administration of the 0.25 mg/ml dose compounds 4 and
5 with DPQ ligand reduced viability by 60 and 20%, respectively,
by 72 h. In the case of the DPPN derivatives 8 and 9 the reduced
viability was of 20% (72 h) while no significant decrease in viability
at this dose over 72 h was observed for the complexes 6 and 7with
DPPZ moiety. All drugs at a concentration of 0.5 or 1 mg/ml proved
toxic to larvae and resulted in 80 – 100% death at 72 h (Fig. 1 for
compound 4 and 11-16S in SI for compound 5 – 9).
In order to determine if the drugs had in vivo antibacterial activ-

































Fig. 3. % Viability of larvae treated with 1:2 dilution of S. aureus and 0.25 mg/mL of the tested complexes. Standard error was less than ± 10% of the mean in all cases.
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toxic dose of each drug at a concentration of 0.1 or 0.25 mg/mL. In
the first series of experiments, which used a drug dose of 0.1 mg/
mL, administration of the bacteria to larvae resulted in 60% kill
after 24 h (Fig. 2). In contrast those larvae administered with com-
plexes 4 to 8 showed viability of 80 – 60% at 24 h and this did not
change significantly by 48 h (Fig. 2). In a second series of experi-
ments the ability of the complexes to prevent larvae from infection
was assessed with higher concentration, 0.25 mg/mL (Fig. 3). In
this experiment complexes 8 and 9 induced 100% survival of larvae
at 24 h and 80% at 48 h.
DPPN derivatives 8 and 9 show very high in vivo activity only at
higher concentration (0.25 mg/ml) while the DPPZ analogues 6 and
7 show the opposite behaviour (more active at lower concentra-
tion). The in vivo antimicrobial activity of the complexes does not
strongly correlate with what was seen in vitro but this is quite
common since the conditions in vivo are much different from those
in vitro; the same lack of correlation was recently observed by our
group with Au(I) complexes [17]. The role of the steroids and of the
planar ligands in the activity of this series of Cu(II) complexes is
not completely clear; the enhanced lipophlicity due to presence
of the steroids that increase the bacterial uptake could explain in
part the high antimicrobial activity but other mechanisms can be
involved. A deeper investigation that will need the use of pro-
teomics analyses is required and planned to clarify this aspect
and will be the object of a future paper.
5. Conclusions
The six novel Cu(II)-steroid complexes showed high potency
in vitro against S. aureus and MRSA and in vivo against S. aureus.When inoculated with the complexes larval viability noticeably
increased in those larvae that were previously infected with S. aur-
eus. The effect of the steroids on the antimicrobial activity of the
metal complexes is still not clarified and we are currently using
proteomics analyses to uncover the mechanism of action. These
complexes show great potential to become lead compounds which
could eventually be developed into new treatments for S. aureus
and possibly MRSA infections.Acknowledgments
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